Literature DB >> 1988075

Variant human breast tumor estrogen receptor with constitutive transcriptional activity.

S A Fuqua1, S D Fitzgerald, G C Chamness, A K Tandon, D P McDonnell, Z Nawaz, B W O'Malley, W L McGuire.   

Abstract

Since progesterone receptor (PgR) is normally induced by estrogen, breast cancer lacking estrogen receptor (ER) would also be expected to lack PgR. However, a small percentage of breast cancers are ER- yet PgR+. These tumors might possess an ER which is defective in estrogen binding but is still functional in stimulating estrogen-responsive genes such as PgR. We have now detected such a variant, lacking exon 5 of the hormone-binding domain, using complementary DNA amplified by the polymerase chain reaction. This variant was the predominate ER RNA expressed in three ER-/PgR+ tumors. Furthermore, the variant ER constitutively activates transcription of a normally estrogen-dependent gene construct in yeast cells. The variant ER could explain the expression of PgR in certain tumors and have therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988075

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  80 in total

Review 1.  Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones.

Authors:  R K Hansen; M J Bissell
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

2.  Analysis of estrogen receptor messenger RNA in breast carcinomas from archival specimens is predictive of tumor biology.

Authors:  C Carmeci; E C deConinck; T Lawton; D A Bloch; R J Weigel
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

3.  Expression of estrogen receptor variant messenger RNAs and determination of estrogen receptor status in human breast cancer.

Authors:  A Huang; E R Leygue; L Snell; L C Murphy; P H Watson
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

4.  Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.

Authors:  V Craig Jordan; Ramona Curpan; Philipp Y Maximov
Journal:  J Natl Cancer Inst       Date:  2015-04-02       Impact factor: 13.506

5.  Identification of novel steroid-response elements.

Authors:  Z Nawaz; M J Tsai; D P McDonnell; B W O'Malley
Journal:  Gene Expr       Date:  1992

Review 6.  Mechanisms of aromatase inhibitor resistance.

Authors:  Cynthia X Ma; Tomás Reinert; Izabela Chmielewska; Matthew J Ellis
Journal:  Nat Rev Cancer       Date:  2015-05       Impact factor: 60.716

7.  Triple primer polymerase chain reaction. A new way to quantify truncated mRNA expression.

Authors:  E Leygue; L Murphy; F Kuttenn; P Watson
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

8.  Classification of breast cancer cells on the basis of a functional assay for estrogen receptor.

Authors:  D K Biswas; L Averboukh; S Sheng; K Martin; D S Ewaniuk; T F Jawde; F Wang; A B Pardee
Journal:  Mol Med       Date:  1998-07       Impact factor: 6.354

9.  Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA).

Authors:  Maria D Corte; Juan A Rodil; Julio Vázquez; Lucia García; Juan C Rodríguez; Miguel Bongera; José C Fernández; Luis O González; Ma Luz Lamelas; Maite Allende; José L García-Muñiz; Antonio Fueyo; Francisco J Vizoso
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-01       Impact factor: 4.553

10.  Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay.

Authors:  G Saccani Jotti; S R Johnston; J Salter; S Detre; M Dowsett
Journal:  J Clin Pathol       Date:  1994-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.